Manhattan Genomics has emerged, aiming to edit human embryos to eliminate genetic diseases, reigniting ethical concerns over gene editing. This matters as it raises questions about the implications of heritable genetic modifications.

Manhattan Genomics, a startup founded by Cathy Tie and Eriona Hysolli, is reigniting the debate on gene-edited babies by targeting genetic diseases at the embryo stage. This initiative follows the controversial work of Chinese scientist He Jiankui, who faced backlash for creating gene-edited embryos in 2018. The company has assembled a team of scientific contributors, including IVF specialists and reproductive biologists, to explore the potential of gene editing to correct harmful mutations. While the technology promises to eliminate diseases like Huntington's and cystic fibrosis, it also raises ethical concerns about unintended consequences and the potential for eugenics. The startup plans to conduct initial studies in animal models before considering human trials, which face significant regulatory hurdles. Despite the challenges, Tie emphasizes the importance of pursuing this research to address genetic diseases, reflecting a growing interest in the field.